PMID- 16955745
OWN - NLM
STAT- MEDLINE
DCOM- 20071102
LR  - 20071115
IS  - 0301-1208 (Print)
IS  - 0301-1208 (Linking)
VI  - 43
IP  - 1
DP  - 2006 Feb
TI  - Antibodies against 9-O-acetylated sialic acids in childhood acute lymphoblastic 
      leukemia: a two-year study with 186 samples following protocol MCP 943.
PG  - 7-14
AB  - Initial studies have revealed an enhanced surface expression of 9-O-acetylated 
      sialoglycoconjugates (9-OAcSGs) on lymphoblasts concomitant with high titers of 
      antibodies (anti-9-OAcSGs) in childhood acute lymphoblastic leukemia (ALL). This 
      study was undertaken in 186 coded samples from 69 ALL patients to evaluate if 
      antibodies against these sialoglycans could monitor response to the treatment. An 
      ELISA was developed using bovine submaxillary mucin (BSM) containing high % of 
      9-O-acetylated sialic acids (9-OAcSA) as the capture antigen, to investigate 
      serum levels of anti 9-OAcSGs in a single-center series of pediatric, 
      clinically-diagnosed and immunophenotypically confirmed ALL patients, as compared 
      to 130 healthy controls. At presentation, a 3.8-fold increase in anti-9-OAcSGs 
      levels was detected in 63/69 ALL patients (mean +/- SEM was 102.8 +/- 6.3 
      microg/ml) as compared to normal controls (27.17 +/- 0.76 microg/ml), assay 
      sensitivity being 91.3%. On an individual basis (n = 25) in patients who were 
      longitudinally monitored for two years, a significant decline in their mean +/- 
      SEM of OD405 was observed from 0.85 +/- 0.06 to 0.28 +/- 0.03. Additionally, a 
      dot-blot was developed to evaluate the proportion of immune-complexed 9-OAcSGs in 
      these patients employing achatinin-H, a 9-OAcSA-binding lectin. Our data indicate 
      that these economically viable ELISA-based approaches allow for reliable, 
      sensitive and rapid diagnosis of ALL. We contend that these disease-specific 
      antibodies could be considered as potential markers both for the initial 
      diagnosis of ALL and possibly for longitudinal monitoring of the disease.
FAU - Bandyopadhyay, Suman
AU  - Bandyopadhyay S
AD  - Immunobiology Division, Indian Institute of Chemical Biology, Kolkata, India.
FAU - Chatterjee, Mitali
AU  - Chatterjee M
FAU - Banavali, Shripad D
AU  - Banavali SD
FAU - Pal, Santanu
AU  - Pal S
FAU - Nair, Chandrika N
AU  - Nair CN
FAU - Advani, Suresh H
AU  - Advani SH
FAU - Mandal, Chitra
AU  - Mandal C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - Indian J Biochem Biophys
JT  - Indian journal of biochemistry & biophysics
JID - 0310774
RN  - 0 (Antibodies)
RN  - 0 (Sialic Acids)
RN  - 55717-54-9 (9-O-acetyl-N-acetylneuraminic acid)
SB  - IM
MH  - Adolescent
MH  - Antibodies/*blood
MH  - Antineoplastic Combined Chemotherapy Protocols/pharmacology
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Male
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis/*drug 
      therapy/*immunology
MH  - Sialic Acids/*immunology
EDAT- 2006/09/08 09:00
MHDA- 2007/11/06 09:00
CRDT- 2006/09/08 09:00
PHST- 2006/09/08 09:00 [pubmed]
PHST- 2007/11/06 09:00 [medline]
PHST- 2006/09/08 09:00 [entrez]
PST - ppublish
SO  - Indian J Biochem Biophys. 2006 Feb;43(1):7-14.